Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioXcel Therapeutics Inc

Current price
1.86 USD 0 USD (0.00%)
Last closed 1.86 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 69 807 288 USD
Yield for 12 month -90.18 %
21.11.2021 - 28.11.2021

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Address: 555 Long Wharf Drive, New Haven, CT, United States, 06511

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

8.25 USD

P/E ratio

Dividend Yield

Current Year

+1 380 000 USD

Last Year

+375 000 USD

Current Quarter

+582 000 USD

Last Quarter

+376 000 USD

Current Year

-198 000 USD

Last Year

+355 000 USD

Current Quarter

+424 000 USD

Last Quarter

-416 000 USD

Key Figures BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -140 268 000 USD
Operating Margin TTM -4151.72 %
PE Ratio
Return On Assets TTM -66.96 %
PEG Ratio
Return On Equity TTM -1766.94 %
Wall Street Target Price 8.25 USD
Revenue TTM 1 756 000 USD
Book Value -2.15 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 182.5 %
Dividend Yield
Gross Profit TTM 355 000 USD
Earnings per share -5.18 USD
Diluted Eps TTM -5.18 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BTAI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 90.4604
Price Sales TTM 64.2554
Enterprise Value EBITDA -0.7547
Price Book MRQ 3.9656

Financials BTAI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BTAI

For 52 weeks

1.79 USD 22.06 USD
50 Day MA 2.53 USD
Shares Short Prior Month 1 502 004
200 Day MA 3.17 USD
Short Ratio 3.62
Shares Short 1 631 200
Short Percent 5.37 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics